ライフサイエンスコーパス: smallpox vaccination

1 y to CMV and vaccinia virus (previous DryVax smallpox vaccination).

2 esponses to nonvaccinia OPXV infections from smallpox vaccination.

3 lular immunity in subjects following primary smallpox vaccination.

4 ccount for differences in immune response to smallpox vaccination.

5 d areas, male gender, age < 15, and no prior smallpox vaccination.

6 ing to blindness is a severe complication of smallpox vaccination.

7 als who experienced adverse events following smallpox vaccination.

8 reviously assessed for clinical responses to smallpox vaccination.

9 udies focusing on CD4(+) T cell responses to smallpox vaccination.

10 likelihood of the development of fever after smallpox vaccination.

11 ightened the interest in the reinitiation of smallpox vaccination.

12 lay a role in ischemic events observed after smallpox vaccination.

13 potentially be maintained for decades after smallpox vaccination.

14 une individuals at 13, 29 and 48 years after smallpox vaccination.

15 sCD40L did not significantly increase after smallpox vaccination.

16 atients with chest pain within 30 days after smallpox vaccination.

17 of illness may be affected by age and prior smallpox vaccination.

18 dest clinical course had previously received smallpox vaccination.

19 reatment regimens against complications from smallpox vaccination.

20 embers and DoD civilian workers eligible for smallpox vaccination.

21 entially lethal complication associated with smallpox vaccination.

22 iated cardiac myocyte necrosis shortly after smallpox vaccination.

23 in vaccinia-naive adult volunteers following smallpox vaccination.

24 virus vaccine complications that occur from smallpox vaccination.

25 now that populations do not receive routine smallpox vaccination.

26 ed an expected adverse event associated with smallpox vaccination.

27 gnited a debate about whether to reintroduce smallpox vaccination.

28 s with preexisting immunity to vaccinia from smallpox vaccination.

29 of antiviral immunity induced by one or more smallpox vaccinations.

30 Prevention estimated rate of death owing to smallpox vaccination (1 in 1,000,000), and many failed t

31 In 5.5 months, the DoD administered 450 293 smallpox vaccinations (70.5% primary vaccinees and 29.5%

32 nting with chest pain 4 to 30 days following smallpox vaccination and be aware of the implications as

33 sk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the

34 eratitis is a serious complication following smallpox vaccination and can lead to blindness.

35 ency, attributed in part to the cessation of smallpox vaccination and concomitant waning of populatio

36 4, 2003, a US Army soldier received primary smallpox vaccination and experienced a primary uptake re

37 s followed by Dryvax increases the safety of smallpox vaccination, and they highlight the importance

38 hat the levels of immunity induced following smallpox vaccination are comparable in magnitude to that

39 t 2.4% of the cohort would be ineligible for smallpox vaccination because of active skin disease in t

40 als with atopic dermatitis are excluded from smallpox vaccination because of their propensity to deve

41 roximately 50% of the US population received smallpox vaccinations before routine immunization ceased

42 studies have shown long-term immunity after smallpox vaccination, but skepticism remains as to wheth

43 dentifying dermatologic contraindications to smallpox vaccination by relying only on a self-reported

44 Thirty years after mass smallpox vaccination campaigns ceased, human monkeypox i

45 During the recent smallpox vaccination campaigns, ischemic cardiac complic

46 eased significantly due to cessation of mass smallpox vaccination campaigns.

47 Mass smallpox vaccinations can be conducted safely with very

48 In anticipation of large-scale smallpox vaccination, clinical trials of new vaccine can

49 ely beneficial in myopericarditis related to smallpox vaccination, compared with other types of myope

50 Recent studies on immunity following smallpox vaccination demonstrate that T-cell memory decl

51 With the reintroduction of smallpox vaccination, detailed contemporary descriptions

52 myo/pericarditis was observed during the US smallpox vaccination (DryVax) campaign initiated in 2002

53 Immune memory after smallpox vaccination (DryVax) is a valuable benchmark fo

54 ccinia virus (VV) infection, mimicking human smallpox vaccination, greatly increased expression of th

55 terrorism, dermatologist knowledge regarding smallpox vaccination has not been extensively examined.

56 The reinitiation of smallpox vaccination has renewed interest in implementin

57 zed that individuals who develop fever after smallpox vaccination have genetically determined differe

58 factor (IRF1) were associated with AEs after smallpox vaccination in 2 independent study samples.

59 estimated the effectiveness of postexposure smallpox vaccination in preventing or modifying disease

60 Smallpox vaccination induced significantly larger skin l

61 Fever after smallpox vaccination is associated with specific haploty

62 ential use of smallpox virus as a bioweapon, smallpox vaccination is currently being reintroduced.

63 prompts the question of whether cessation of smallpox vaccination is driving the phenomenon, and if s

64 acaques and have demonstrated that, although smallpox vaccination is safe in immunodeficient macaques

65 A case study on the effect of smallpox vaccination is used to compare the results obta

66 Widespread dermatologist smallpox vaccination knowledge deficits pinpoint opportu

67 is increasing due to the absence of routine smallpox vaccination leading to a higher proportion of n

68 ant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit asse

69 lls and greatly impeded development of mouse smallpox vaccination models.

70 Eczema vaccinatum (EV) is a complication of smallpox vaccination occurring in patients with atopic d

71 The United States recently implemented smallpox vaccination of selected military personnel in a

72 of Defense resumed a program for widespread smallpox vaccinations on December 13, 2002.

73 nation reported to the Department of Defense Smallpox Vaccination Program.

74 Our experience suggests that broad smallpox vaccination programs may be implemented with fe

75 e that, in addition to the CD8 response, the smallpox vaccinations raised a robust CD4 response with

76 The resumption of smallpox vaccinations raises important questions regardi

77 Following successful eradication of smallpox, vaccination rates with the smallpox vaccine ha

78 ression changes in 197 recipients of primary smallpox vaccination representing the extremes of humora

79 have a number of beliefs about smallpox and smallpox vaccination that are false.

80 Eczema vaccinatum (EV) is a complication of smallpox vaccination that can occur in persons with ecze

81 virus keratitis (VACVK) is a complication of smallpox vaccination that can result in blindness.

82 Despite the success of smallpox vaccination, the immunological correlates of pr

83 Specific recommendations are made regarding smallpox vaccination, therapy, postexposure isolation an

84 Smallpox vaccination was historically the most effective

85 , 18 cases of probable myopericarditis after smallpox vaccination were reported (an incidence of 7.8

86 No cases of myopericarditis following smallpox vaccination were reported among 95,622 vaccinee

87 ivity against vaccinia virus, as a result of smallpox vaccination, which may limit its use as a vecto

88 We have modeled smallpox vaccination with Dryvax (Wyeth) in rhesus macaq

89 een candidate SNPs and antibody levels after smallpox vaccination with P < .05.

90 has been a rare or unrecognized event after smallpox vaccinations with the New York City Board of He

91 cases of myopericarditis per million primary smallpox vaccinations with this strain of vaccinia virus

92 V) related to MPXV) and cessation of routine smallpox vaccination (with the live OPXV vaccinia), ther

93 as remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses th

94 It is unknown whether smallpox vaccination would protect human immunodeficienc